779199-69-8

Basic information

• Product Name: Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate
• Synonyms: Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate;Methyl 1-(4-hydroxyphenyl)cyclopropanecarboxylate;1-(4-hydroxy-phenyl)-cyclopropanecarboxylic acid methyl ester
• CAS NO: 779199-69-8
• Molecular Formula: C₁₁H₁₂O₃
• Molecular Weight: 192.21118
• Mol File: 779199-69-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 303.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.265±0.06 g/cm3(Predicted)
• PKA: 10.18±0.15(Predicted)
• CAS DataBase Reference: Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate(779199-69-8)
• EPA Substance Registry System: Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate(779199-69-8)

Safety Data

• Hazardous Substances Data: 779199-69-8(Hazardous Substances Data)

Usage

General Description

Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate is a chemical compound that belongs to the class of cyclopropane carboxylates. It is characterized by the presence of a cyclopropane ring structure and a carboxylate group, as well as a phenyl ring with a hydroxyl group attached at the para position. Methyl 1-(4-hydroxyphenyl)cyclopropane-1-carboxylate has potential applications in organic synthesis and medicinal chemistry, due to its unique structure and reactivity. It can be used as a building block for the synthesis of various pharmaceuticals and biologically active molecules. Additionally, its cyclopropane moiety can impart unique properties and activities to the compounds it is incorporated into, making it an interesting and valuable chemical building block.

Upstream product

• 779206-51-8 1-(4-methoxyphenyl)cyclopropanecarboxylic acid methyl ester 
• 16728-01-1 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 68641-16-7 (4-benzyloxy-phenyl)-acetic acid methyl ester 
• 111751-72-5 methyl 2-(4'-benzyloxyphenyl)propenoate 

Downstream Products

• 936727-39-8 1-(4-hydroxy-3,5-diiodophenyl)cyclopropanecarboxylic acid methyl ester 
• 1428900-38-2 1-{4-[3-(4-fluorophenoxy)-5-{[(4-hydroxy-4-isobutyl-1-piperidinyl)carbonyl]amino}phenoxy]phenyl}cyclopropanecarboxylic acid 
• 936727-45-6 1-(2,3-dihydrobenzofuran-5-yl)cyclopropanecarboxylic acid 
• 952664-59-4 1-[4-(2-carboxyethoxy)phenyl]cyclopropanecarboxylic acid methyl ester 
• 936727-40-1 1-[3,5-diiodo-4-(2-methyl-allyloxy)phenyl]cyclopropanecarboxylic acid methyl ester 
• 936727-44-5 1-(benzofuran-5-yl)cyclopropanecarboxylic acid 
• 952664-58-3 1-[4-(2-tert-butoxycarbonyl-ethoxy)phenyl]cyclopropanecarboxylic acid methyl ester 

Relevant articles and documents

Site-Selective C?H Oxygenation via Aryl Sulfonium Salts

Herein, we report a two-step process forming arene C?O bonds in excellent site-selectivity at a late-stage. The C?O bond formation is achieved by selective introduction of a thianthrenium group, which is then converted into C?O bonds using photoredox chemistry. Electron-rich, -poor and -neutral arenes as well as complex drug-like small molecules are successfully transformed into both phenols and various ethers. The sequence differs conceptually from all previous arene oxygenation reactions in that oxygen functionality can be incorporated into complex small molecules at a late stage site-selectively, which has not been shown via aryl halides.

PHARMACEUTICALS COMPRISING BIARYL DERIVATIVES OR SALTS THEREOF

PROBLEM TO BE SOLVED: To provide compounds with excellent antimycotic activity against Trichophyton. SOLUTION: The invention provides pharmaceuticals comprising biaryl derivatives represented by general formula (I) or salts thereof, where ring A is optionally substituted phenyl or the like; Q is CH2 or the like; X1, X2 and X3 are CR1 or the like; and Y is CH or N. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.